Theory Paper IIDrNB Cardiology – Theory Notes

ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR (ARNI): CURRENT STATUS & EVIDENCE

2-page exam answerLast reviewed: October 2026
Merit MedScript seal

IPHARMACOLOGICAL MECHANISM AND THE “WASHOUT” MANDATE

  • The Dual Pathway: Angiotensin Receptor-Neprilysin Inhibitor (ARNI: Sacubitril/Valsartan) simultaneously blocks the Renin-Angiotensin-Aldosterone System (RAAS) and enhances the endogenous natriuretic peptide system.
  • Sacubitril: A prodrug that inhibits neprilysin, preventing the degradation of Atrial and Brain Natriuretic Peptides (ANP/BNP), bradykinin, and adrenomedullin, which promotes vasodilation, natriuresis, and anti-fibrotic effects.
  • Valsartan: An AT1 receptor blocker that mitigates the reflex RAAS overactivation caused by baseline heart failure and neprilysin inhibition.
  • The Angioedema Trap: Both neprilysin and Angiotensin-Converting Enzyme (ACE) degrade bradykinin; combining Sacubitril with an ACE inhibitor causes massive bradykinin accumulation and life-threatening angioedema.
  • Mandatory Washout Rule: A strict 36-hour washout period is mandatory when switching a patient from an ACE inhibitor to an ARNI. No washout period is required when switching from an ARB to an ARNI.

IILANDMARK CLINICAL TRIAL EVIDENCE

  • PARADIGM-HF (2014) — The Chronic HFrEF Standard:
    • Study Design: Randomized patients with chronic HFrEF (LVEF 40 percent or less, later amended to 35 percent or less) to Sacubitril/Valsartan versus Enalapril.
    • Key Findings: Halted early due to overwhelming efficacy; ARNI demonstrated a 20 percent Relative Risk Reduction (RRR) in the primary composite endpoint of cardiovascular death or heart failure hospitalization, and reduced all-cause mortality by 16 percent.
    • PIONEER-HF (2018) and TRANSITION — The Acute Setting:
    • Key Findings: Proved that initiating ARNI in-hospital for acute decompensated heart failure (once hemodynamically stabilized) is safe, does not increase renal failure or angioedema compared to Enalapril, and yields a significantly greater, rapid reduction in NT-proBNP.
    • PROVE-HF (2019) — Reverse Cardiac Remodeling:
    • Key Findings: Demonstrated that the reduction in NT-proBNP with ARNI directly correlates with true reverse cardiac remodeling (significant increases in LVEF and reductions in LV end-diastolic and end-systolic volumes) at 6 to 12 months.
    • PARAGON-HF (2019) — The HFpEF Spectrum:
    • Key Findings: Evaluated ARNI versus Valsartan in HFpEF (LVEF greater than 45 percent) and narrowly missed statistical significance for its primary endpoint (p = 0.06).
    • Subgroup Nuance: Subgroup analysis demonstrated significant benefit in women and in patients with mildly reduced or “below normal” LVEF (45 to 57 percent).
    • PARADISE-MI (2021) — Post-AMI LV Systolic Dysfunction:
    • Key Findings: Tested ARNI versus Ramipril in patients with acute myocardial infarction and transient LV systolic dysfunction without prior heart failure; failed to show a statistically significant reduction in the primary composite endpoint, meaning ARNI is not a routine replacement for ACE inhibitors in uncomplicated post-MI patients.
Clinical Trial Patient Population Comparator Key Primary Outcome & Clinical Impact
PARADIGM-HF (2014) Chronic HFrEF (LVEF <40%) Enalapril 20% RRR in CV death or HF hospitalization; 16% RRR in all-cause mortality
PIONEER-HF (2018) Acute decompensated HFrEF (in-hospital) Enalapril Safe in-hospital initiation; rapid and superior reduction in NT-proBNP
PROVE-HF (2019) HFrEF (single-arm remodeling study) Baseline NT-proBNP reduction correlated with LVEF increase and LV volume reduction at 6–12 months
PARAGON-HF (2019) HFpEF (LVEF >45%) Valsartan Missed primary endpoint (p = 0.06); significant benefit in women and LVEF 45–57%
PARADISE-MI (2021) Acute MI with transient LVSD Ramipril No significant difference in primary endpoint; not routine over ACEi in uncomplicated post-MI

IIICURRENT GUIDELINE STATUS (ESC 2021/2023 & ACC/AHA 2022)

  • Chronic HFrEF (LVEF less than 40 percent): Class I recommendation (ACC/AHA 2022: de novo or replacing an ACEi/ARB; ESC 2021: as a replacement for an ACEi, with de novo use an option) to further reduce morbidity and mortality, serving as a foundational pillar of Quadruple Therapy (ARNI, Beta-blocker, MRA, SGLT2i).
  • Acute Heart Failure: In-hospital initiation once hemodynamically stable is supported (ACC/AHA 2022 Class IIa for de novo hospitalized HFrEF), in line with the ESC 2023 Class I recommendation for rapid GDMT optimization before discharge.
  • HFmrEF (LVEF 41 to 49 percent) and HFpEF: Class IIb consideration; expanded labeling supports use in heart failure with “below normal” LVEF based on pooled PARAGON-HF data.

IVCLINICAL PITFALLS AND BIOMARKER INTERPRETATION

  • The BNP Trap: Because Sacubitril inhibits neprilysin (the enzyme responsible for degrading active BNP), initiating an ARNI causes an expected, pharmacological elevation in serum BNP.
  • Mandatory Monitoring Rule: Clinicians must solely use NT-proBNP (which is not a neprilysin substrate and accurately falls as ventricular wall stress decreases) rather than BNP to monitor volume status and treatment response in patients taking an ARNI.

VPRACTICAL CONSIDERATIONS IN THE INDIAN CLINICAL CONTEXT

  • Generic Availability and Accessibility: Wide availability of lower-cost generic Sacubitril/Valsartan in India has made it as accessible frontline GDMT in routine Indian practice.
  • The Hypotensive South Asian Phenotype: Indian patients generally have a lower Body Mass Index (BMI) and lower baseline systolic blood pressure than Western trial cohorts, making the PARADIGM-HF target dose of 200 mg twice daily frequently unachievable without inducing symptomatic hypotension or presyncope.
  • Pragmatic Micro-Dosing Strategy: In Indian practice, initiation frequently begins at low doses (50 mg once or twice daily), prioritizing the maintenance of the highest tolerated dose, which still provides substantial diuretic-sparing and prognostic benefits over ACE inhibitors.

Key references

  • McDonagh TA, Metra M, Adamo M, et al.: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (and 2023 Focused Update), European Heart Journal, 2021/2023.
  • Januzzi JL Jr, Prescott MF, Butler J, et al. (PROVE-HF Investigators): Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction, JAMA, 2019.
  • Libby P, Bonow RO, Mann DL, Tomaselli GF, Bhatt DL, Solomon SD: Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine, 12th Ed., Elsevier, 2022.
meritmedscript.comDr. Sidhartha Mullapudi

Was this answer useful?

Your rating helps decide which topics to expand next.

Report an error

Spotted something outdated or incorrect? Tell us and we will check it against the source.